Apogee Therapeutics, Inc.
NASDAQ: APGE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Thomas Henderson
- Employees
- 196
- Headquarters
- Waltham, United States
- IPO year
- 2023
- Market cap
- $5.6B
- Website
- https://www.apogeetherapeutics.com
Loading APGE…
Loading profile data…Frequently asked questions about APGE
What does Apogee Therapeutics, Inc. (APGE) do?
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal a...
Where does APGE trade?
Apogee Therapeutics, Inc. (APGE) trades on the NASDAQ Global Market.
What sector is APGE in?
Apogee Therapeutics, Inc. (APGE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Apogee Therapeutics, Inc.?
Michael Thomas Henderson is the chief executive officer of Apogee Therapeutics, Inc. (APGE).
Where is Apogee Therapeutics, Inc. headquartered?
Apogee Therapeutics, Inc. is headquartered in United States.
Does APGE pay a dividend?
Apogee Therapeutics, Inc. (APGE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did APGE go public?
Apogee Therapeutics, Inc. (APGE) completed its initial public offering in 2023.